Clinical effect of two quadruple therapies on patients with Helicobacter pylori eradication failure
-
摘要: [目的]探讨两种四联方案应用在幽门螺杆菌根除失败的患者中的临床疗效及应用价值。[方法]选择我院进行幽门螺杆菌根除失败患者102例采取随机数字表法分为观察组和对照组,对照组给予以四环素为主的四联方法补救治疗,观察组采取以莫西沙星为主的四联方案补救治疗,记录治疗情况。[结果]观察组治疗总有效率为86.27%,对照组治疗总有效率为64.71%,组间对比差异有统计学意义(χ2=6.4114,P＜0.05)。观察组治疗后白细胞介素-6(13.18±1.33)mg/L,白细胞介素-10(23.86±5.16)mg/L;对照组治疗后白细胞介素-6(23.16±2.47)mg/L,白细胞介素-10(14.15±4.09)mg/L,组间对比差异有统计学意义(t=25.4059、10.5315,P＜0.05)。观察组幽门螺杆菌清除率78.43%,高于对照组幽门螺杆菌清除率56.86%,组间对比差异有统计学意义(χ2=5.4203,P＜0.05)。2组不良反应比较差异无统计学意义(χ2=0.4435,P＞0.05)。[结论]莫西沙星、雷贝拉唑、阿莫西林联合胶体果胶铋的四联方案应用在幽门螺杆菌根除失败患者中是一种有效的补救治疗方法,能够改善患者炎症状态,效果可靠,值得在临床大力推广使用。Abstract: [Objective] To investigate the clinical curative effect of two kinds of quadruple therapies in the treatment of patients with Helicobacter pylori eradication failure.[Methods] 102 cases of patients with helicobacter pylori eradication failure were divided into observation group and control group randomly.The former was given quadruple therapy based on moxifloxacin as remedial treatment.The latter was given quadruple therapy based on tetracycline.Curative effect was observed.[Results] The total effective rate of the observation group was 86.27%,which was significantly higher than that of the control group,64.71%(P＜0.05).After the treatment,interleukin-6 level in the observation group and the control group was 13.18 ± 1.33 mg/L and 23.16 ± 2.47 mg/L respectively,interleukin-10 level was 23.86 ±5.16 mg/L and 14.15±4.09 mg/L respectively,the difference between the two groups was statistically significant(P＜0.05).The helicobacter pylori clearance rate of the observation group was 78.43%,higher than that of the control group,56.86%,(P＜0.05).The adverse reaction was similar between the two groups,with no statistically significant difference(chi-square=0.4435,P＞0.4435).[Conclusion] Quadruple therapy of moxifloxacin,rabeprazole combined with Colloidal bismuth pectin and amoxicillin applied in patients with helicobacter pylori eradication failure was effective in improving inflammatory state of the patients,deserving to be popularized in clinical application.
-
Key words:
- helicobacter pylori /
- remedial therapy /
- quadruple therapy
-
-
[1] 龚家顺, 彭惠容, 刘芬, 等.以莫西沙星为主的三联疗法在幽门螺杆菌感染首次根除失败患者中应用价值[J].胃肠病学和肝病学杂志, 2014, 23(7):274-279.
[2] 陈益忠.雷贝拉唑, 莫西沙星, 阿莫西林联合治疗幽门螺杆菌阳性消化性溃疡的疗效观察[J].上海医药, 2012, 33(1):19-20.
[3] 中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌研究协作组.第四次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志, 2012, 51(10):832-837.
[4] 李明.幽门螺杆菌感染的治疗现状[J].齐齐哈尔医学院学报, 2013, 34(6):864-865.
[5] 王琴, 王菲, 张定国, 等.埃索美拉唑联合左氧氟沙星、阿莫西林克拉维酸钾治疗幽门螺杆菌l4天疗程临床观察[J].临床消化病杂志, 2011, 23(5):281-282.
[6] 王淑君, 王蔚虹, 褚云香, 等.不含铋剂四联疗法与标准三联疗法根除幽门螺杆菌的效果分析[J].中华医学杂志, 2014, 94(1):576-579.
[7] 周小红.四联疗法治疗幽门螺杆菌阳性消化性溃疡临床疗效分析[J].中国药物经济学, 2014, 5(1):237-238.
[8] 程小华.3种抗幽门螺杆菌的四联疗法在消化性溃疡中的疗效观察[J].中国临床实用医学, 2014, 7(1):50-51.
[9] 辛智武, 鲍有光, 龙洪波.四联疗法治疗幽门螺杆菌阳性消化性溃疡45例临床观察[J].基层医学论坛, 2014, 29(1):3947-3949.
[10] 刘展, 张渝, 阳佳, 等.铋剂四联疗法根治幽门螺杆菌的临床观察[J].国际消化病杂志, 2014, 34(1):149-150.
[11] 张慧, 毛峻岭, 张丽航, 等.10日序贯疗法与标准三联疗法根治幽门螺杆菌的疗效比较[J].临床荟萃, 2011, 11(7):879-881.
[12] 高文, 成虹, 胡伏莲, 等.含艾普拉唑四联七天疗法根除幽门螺杆菌的全国多中心临床研究[J].中华医学杂志, 2012, 92(30):2108-2112.
[13] 周文斌, 李志英.含雷贝拉唑四联初治方案根除幽门螺杆菌疗效观察[J].中国当代医药, 2011, 18(2):45-45.
[14] 肖俏霞, 尹庆和, 林冬红, 等.四联疗法与常规三联疗法对幽门螺杆菌首次根除失败患者炎症因子的影响以及疗效对比[J].中国中西医结合消化杂志, 2015, 23(5):366-367.
[15] 刘文桂.含左氧氟沙星的四联方案补救治疗幽门螺杆菌感染的临床分析[J].海南医学, 2013, 23(13):35-36.
-
计量
- 文章访问数: 185
- PDF下载数: 155
- 施引文献: 0
下载: